Search research articles
Contact Us
Filters
Showing results (121-130 of 141) with videos related to
Page
of 15
Sort By:
Leukemia & Lymphoma
|
July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2009
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus
Lucia Nogová, Ronald Boellaard, Carsten Kobe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Plos One
|
March 11, 2016
Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma
Regine Kluge, Lidia Chavdarova, Martha Hoffmann, et al.
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Hemasphere
|
January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
Conrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
Blood
|
September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 141) with videos related to
Sort By:
Page
of 15
Leukemia & Lymphoma
|
July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2009
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus
Lucia Nogová, Ronald Boellaard, Carsten Kobe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Plos One
|
March 11, 2016
Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma
Regine Kluge, Lidia Chavdarova, Martha Hoffmann, et al.
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Hemasphere
|
January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
Conrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
Blood
|
September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Page
of 15